Related references
Note: Only part of the references are listed.The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer
Marie Klintman et al.
MODERN PATHOLOGY (2010)
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics
Goran Jonsson et al.
BREAST CANCER RESEARCH (2010)
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2009)
Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers
Jan P. A. Baak et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer
Cecilia Ahlin et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients
R. Stuart-Harris et al.
BREAST (2008)
Cell cycle dysregulation influences survival in high risk breast cancer patients
Robert Koenigsberg et al.
CANCER INVESTIGATION (2008)
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
Christine Desmedt et al.
CLINICAL CANCER RESEARCH (2008)
Ki67 and cyclin A as prognostic factors in early breast cancer.: What are the optimal cut-off values?
C. Ahlin et al.
HISTOPATHOLOGY (2007)
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
E. de Azambuja et al.
BRITISH JOURNAL OF CANCER (2007)
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer
Andrew E. Teschendorff et al.
GENOME BIOLOGY (2007)
International Web-based consultation on priorities for translational breast cancer research
Mitch Dowsett et al.
BREAST CANCER RESEARCH (2007)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M. McShane et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer
Anna V. Ivshina et al.
CANCER RESEARCH (2006)
Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis
C Sotiriou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer
P Poikonen et al.
BRITISH JOURNAL OF CANCER (2005)
Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index:: reproducibility of grade and advantages of proliferation index
JS Meyer et al.
MODERN PATHOLOGY (2005)
Good Old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers
P Edén et al.
EUROPEAN JOURNAL OF CANCER (2004)
Prognostic value of proliferation in invasive breast cancer: a review
PJ van Diest et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer
P Rudolph et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer
H Kühling et al.
JOURNAL OF PATHOLOGY (2003)
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment
R Michalides et al.
BRITISH JOURNAL OF CANCER (2002)
Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas
IRK Bukholm et al.
INTERNATIONAL JOURNAL OF CANCER (2001)